Is vasculitis a significant component of atherosclerosis?

Current Opinion in Rheumatology

Volumn 11, Issue 1, 1999, Pages 3-10

  Juvonen, Tatu ^a   Juvonen, Jukka ^b   Savolainen, Markku J ^a  

^a OULU UNIVERSITY HOSPITAL   (Finland)

^b KAINUU CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ARTERY WALL; ATHEROSCLEROSIS; DISEASE ASSOCIATION; HUMAN; IMMUNITY; INFECTION; INFLAMMATION; PRIORITY JOURNAL; REVIEW; VASCULITIS;

ANIMALS; ARTERIOSCLEROSIS; CHLAMYDIA INFECTIONS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNE SYSTEM DISEASES; VASCULITIS;

EID: 0032931719     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199901000-00002     Document Type: Review

References (93)

1. Braunwald E: Shattuck lecture-cardiovascular medicine at the turn of the millenieum: triumphs, concerns, and opportunities N Engl J Med 1997, 337:1360-1369. This is an excellent review of the history, current state, and future of modern cardiology.
2. Mehta JL, Saldeen TGP, Rand K: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998, 31:1217-1225. This article presents a comprehensive review of risk factors and potential pathophysiologic mechanisms of coronary heart disease.
3. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, et al: Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998, 18:369-378. This article suggests a new pathogenetic mechanism that could explain how modified lipoproteins might affect the immune system and especially how lipoproteins sequestered in the intima could activate the complement system.
4. Iacoviello L, Di Castenuovo A, de Knijff P, D'ORazio A, Amore C, Arboretti R, et al: Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998, 338:79-85.
5. Ylä-Herttuala S: Is oxidized low-density lipoprotein present in vivo? Curr Opin Lipidol 1998, 9:337-344. This is a comprehensive review article outlining the role of oxidized LDL in the early stages of atherosclerosis.
6. Mattila KJ, Valtonen VV, Nieminen MS, Asikainen S: Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke. Clin Infect Dis 1998, 26:719-734.
7. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993, 362:801-809.
8. Stemme S, Hansson GK: Immune mechanism in atherogenesis. Ann Med 1994, 26:141-146.
9. Libby P: Atheroma: more than mush. Lancet 1996, 348(supp1 1):4-7.
10. van der Wal AC, Becker AE, van der Loos CM, Das PK: Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994, 89:36-44.
11. de Servi S, Ricevuti G, Mazzone A, Ghio S, Zito A, Raffaghello S, Specchia G: Granulocyte function in coronary artery disease. Am J Cardiol 1991, 68:64B-68B.
12. Mazzone A, De Servi S, Ricevuti G, Mazzucchelli I, Fossati G, Pasotti D, et al: Increased expression of neutrophil and monocyte adhesion molecules in unstable coronary artery disease Circulation 1993, 88 358-363.
13. Liuzzo G, Biasucci LM, Gallimore JR, Grillo RL, Rebuzzi AG, Pepys MB, Maseri A: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
14. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979. This landmark paper provides evidence that increased levels of C-reactive protein are a significant risk factor for myocardial infarction and raises a question that the effect of an aspirin regimen could be the result of decreased inflammation.
15. Daugherty A, Puré E, Delfel-Butteiger D, Chen S, Leferovich J, Roselaar SE: The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J Clin Invest 1997, 100:1575-1580.
16. Dansky HM, Charlton SA, McGee Harper M, Smith JD: T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 1997, 94:4642-4646.
17. Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci USA 1995, 92:8264-8268.
18. Gupta S, Pablo AM, Jiang X, Wang N, Tall AR, Schindler C: IFN-γ potentiates atherosclerosis in apoE knock-out mice. J Clin Invest 1997, 99:2752-2761.
19. Zhou X, Paulsson G, Stemme S, Hansson GK: Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apoE-knockout mice. J Clin Invest 1998, 101:1717-1725. This detailed study provides evidence for T-cell help with production of Th1-dependent IgG2a antibodies against oxidized LDL that peak during the earliest phase of atherosclerotic lesion and with interferon-γ both in the spleen and in the plaque itself Moreover, it shows that severe hypercholesterolemia is associated with a switch toward a Th2-driven response, with interleukin-4 predominating in the atherosclerotic lesions.
20. Mach F, Schonbeck U, Sukhova GK, Atkinson E, Libby P. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature 1998, 394:200-203. This study demonstrates that atherosclerosis can be reduced by immunomodulatory treatment.
21. Nicoletti A, Kaveri S, Caligiuri G, Bariety J, Hansson GK: Immunoglobulin treatment reduces atherosclerosis in apo E knockout mice. J Clin Invest 1998, 102:910-918. This study also shows reduction of atherosclerotic lesions by immunomodulatory treatment.
22. Hansson GK: Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J 1993, 69(suppl):38-41.
23. Kovanen PT, Mānttari M, Palosuo T, Manninen V, Aho K: Prediction of myocardial infarction in dyslipidemic men by elevated levels of immunoglobulin classes A, E, and G, but not M. Arch Intern Med 1998, 158:1434-1439. A nested case-control study of the Helsinki Heart Study cohort shows evidence for association of elevated IgA, IgE, or IgG with increased nonfatal or fatal myocardial infarction or sudden cardiac death in men with hypertriglyceridemia and low levels of high-density lipoprotein cholesterol.
24. Xu Q, Willeit J, Marosi M, Kleindienst R, Oberhollenzer F, Kiechl S, et al: Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis. Lancet 1993, 341:255-259.
25. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK: T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc Natl Acad Sci U S A 1995, 92:3893-3897.
26. Fabricant CG, Fabricant J, Minick CR, Litrenta MM: Herpesvirus-induced atherosclerosis in chickens. Fed Proc 1983, 42:2476-2479.
27. Adam E, Melnick JL, Probtsfield JL, Petrie BL, Burek J, Bailey KR, et al: High levels of cytomegalovirus antibody in patients requiring vascular surgery for atherosclerosis. Lancet 1987, 2:291-293.
28. Visseren FL, Bouter KP, Pon MJ, Hoekstra JB, Erkelens DW, Diepersloot RJ: Patients with diabetes mellitus and atherosclerosis: a role for cytomegalovirus? Diabetes Res Clin Pract 1997, 36:49-55
29. Sorlie PD, Adam E, Melnick SL, Folsom A, Skelton T, Chambless LE, et al: Cytomegalovirus/herpesvirus and carotid atherosclerosis: the ARIC Study. J Med Virol 1994, 42:33-37.
30. Nieto FJ, Adam E, Sortie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M: Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis. Circulation 1996, 94:922-927.
31. Ossewaarde JM, Feskens EJ, De Vries A, Vallinga CE, Kromhout D: Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998, 120:93-99.
32. Adler SP, Hur JK, Wang JB, Vetrovec GW: Prior infection with cytomegalovirus is not a major risk factor for angiographically demonstrated coronary artery atherosclerosis. J Infect Dis 1998, 177:209-212.
33. Zhou YF, Leon MB, Waclawiw MA, Popma JJ, Yu ZX, Finkel T, Epstein SE: Association between prior cytomegalovirus infection and the risk of restenosis after coronary atherectomy. N Engl J Med 1996, 335:624-630.
34. Blum A, Giladi M, Weinberg M, Kaplan G, Pasternack H, Laniado S, Miller H. High anticytomegalovirus (CMV) IgG antibody titer is associated with coronary artery disease and may predict post-coronary balloon angioplasty restenosis. Am J Cardiol 1998, 81:866-868. This prospective study demonstrates an association between high anti-CMV antibody titer and restenosis after coronary balloon angioplasty. The results suggest that a chronic immunologic response may play a role in atherosclerosis and restenosis.
35. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE: Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989, 261:3561-3566
36. Benditt EP, Barrett T, McDougall JK: Viruses in the etiology of atherosclerosis. Proc Natl Acad Sci U S A 1983, 80:6386-6389.
37. Melnick JL, Adam E, Debakey ME: Cytomegalovirus and atherosclerosis. Eur Heart J 1993, 14(suppl K):30-38.
38. Danesh J, Collins R, Peto R: Chronic infections and coronary heart disease: is there a link? Lancet 1997, 350:430-436. This large and critical review considers the possible role of chronic infection as a cause of coronary artery disease.
39. Chiu B, Vitra E, Tucker W, Fong IW: Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atherosclerosis of the carotid artery. Circulation 1997, 96:2144-2148.
40. Coutts WE, Davila M: Lymphogranuloma venereum as a possible cause of arteriosclerosis and other arterial conditions. J Trop Med Hyg 1945, 48:46-51.
41. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH, et al: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988, 2:983-986.
42. Saikku P, Leinonen M, Tenkanen L, Linnanmäki E, Ekman MR, Manninen V, et al: Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study. Ann Intern Med 1992, 116:273-278.
43. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS, Daling JR: Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. JAMA 1992, 268:68-72.
44. Mendall MA, Carrington D, Strachan D, Patel P, Molineaux N, Levi J, et al: Chlamydia pneumoniae: risk factors for seropositivity and association with coronary heart. J Infect 1995, 30:121-128.
45. Miettinen H, Lehto S, Saikku P, Haffner SM, Ronnemaa T, Pyörälä K, Laakso M: Association of Chiamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996, 17:682-688.
46. Leinonen M, Linnanmäki E, Mattila K, Nieminen MS, Valtonen V, Leirisalo-Repo M, Saikku P: Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog 1990, 9:67-73.
47. Linnanmäki E, Leinonen M, Mattila K, Nieminen M, Valtonen V, Saikku P: Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease. Circulation 1993, 87:1130-1134.
48. Shor A, Kuo CC, Patton DL. Detection of Chlamydia pneumoniae in coronary arterial fatty streaks and atheromatous plaques. S Afr Med J 1992, 82:158-161.
49. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT: Demonstration of Clamidia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis 1993, 167:841-849.
50. Kuo CC, Grayston JT, Campbell LA, Goo YA, Wissler RW, Benditt EP: Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old). Proc Natl Acad Sci U S A 1995, 92:6911-6914
51. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ, et al: Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation 1995, 92:3397-3400.
52. Muhlestein JB, Hammond EH, Carlquist JF, Radicke E, Thomson MJ, Karagounis LA, et al: Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease. J Am Coll Cardiol 1996, 27:1555-1561.
53. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A, Grayston JT: Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997, 176:292-295.
54. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. The Chlamydia pneumoniae/Atherosclerosis Study Group. Ann Intern Med 1996, 125:979-982.
55. Maass M, Bartels C, Engel PM, Mamat U, Sievers HH: Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998, 31:827-832. Even though C. pneumoniae has been difficult to isolate from the arterial wall, these authors demonstrate that this endeavor is not insurmountable.
56. Fong IW, Chiu B, Vitra E, Fong MW, Jang D, Mahony J: Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol 1997, 35:48-52.
57. Moazed TC, Kuo C, Grayston JT, Campbell LA: Murine models of Chlamydia pneumoniae infection and atherosclerosis J Infect Dis 1997, 175:883-890.
58. Laitinen K, Laurila A, Pyhalä L, Leinonen M, Saikku P. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits. Infect Immun 1997, 65:4832-4835.
59. Muhlestein JB, Anderson JL, Hammond EH, Zhao L, Trehan S, Schwobe EP, Carlquist JF: Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model. Circulation 1998, 97:633-636. Using a chronic animal model, the authors demonstrate that C. pneumoniae infection leads to atherosclerotic lesions and that development of these lesions could be prevented by antibiotic regimens.
60. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997, 96:404-407. This article provides the first evidence that antibiotic treatment decreases the rate of cardiovascular events in patients with coronary artery disease.
61. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. Lancet 1997, 350:404-407. This study confirms the effect of antibiotics for treatment of coronary artery disease.
62. Siniasalo J, Mattila K, Nieminen MS, Valtonen V, Syrjälä M, Sundberg S, Saikku P: The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998, 41:85-92.
63. Pesonen E. Infection and intimai thickening: evidence from coronary arteries in children. Eur Heart J 1994, 15(suppl C):57-61.
64. Mendall MA, Goggin PM, Molineaux N, Levy J, Toosy T, Strachan D, et al: Relation of Helicobacter pylori infection and coronary heart disease. Br Heart J 1994, 71:437-439.
65. Folsom AR, Nieto FJ, Sorlie P, Chambless L, Graham DY: Helicobacter pylori seropositivity and coronary heart disease incidence. Circulation 1998, 98:845-850. This excellent study did not find association between coronary artery disease and H. pylori seropositivity.
66. Pascen V, Cammarota G, Patti G, Cuoco L, Gasbarrini A, Grillo RL, et al: Association of virulent Helicobacter pylori strains with ischemic heart disease. Circulation 1998, 97:1675-1679.
67. Mattila KJ, Nieminen MS, Valtonen VV, Rasi VP, Kesäniemi YA, Syrjäla SL, et al: Association between dental health and acute myocardial infarction. BMJ 1989, 298:779-781.
68. Mattila K, Valtonen VV, Nieminen M, Huttunen J: Dental infection and the risk of new coronary events: prospective study of patients with documented coronary artery disease. Clin Infect Dis 1995, 20:588-592.
69. Libby P, Egan D, Skarlatos S: Roles of infectious agents in atherosclerosis and restenosis: an assessment of the evidence and need for future research. Circulation 1997, 96:4095-4103.
70. Lopes-Virella MF: Interactions between bacterial lipopolysaccharides and serum lipoproteins and their possible role in coronary heart disease. Eur Heart J 1993, 14(suppl K):118-124.
71. Nieminen MS, Mattila K, Valtonen V: Infection and inflammation as risk factors for myocardial infarction. Eur Heart J 1993, 14(suppl K):12-16.
72. Cook PJ, Lip GY: Infectious agents and atherosclerotic vascular disease. QJM 1996, 89:727-735.
73. Van Dam-Mieras MC, Bruggeman CA, Muller AD, Debie WH, Zwaal RF: Induction of endothelial cell procoagulant activity by cytomegalovirus infection. Thromb Res 1987, 47:69-75.
74. Kaukoranta-Tolvanen SS, Laitinen K, Saikku P, Leinonen M: Chlamydia pneumoniae multiplies in human endothelial cells in vitro. Microb Pathog 1994, 16:313-319.
75. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC: Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996, 64:1614-1620.
76. Beatty WL, Morrison RP, Byrne GI: Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994, 58:686-699.
77. Ward ME: The immunobiology and immunopathology of chlamydial infections. APMIS 1995, 103:769-796.
78. Schachter J: Pathogenesis of chlamydial infections. Pathol Immunopathol Res 1989, 8:206-220.
79. Grayston JT, Wang SP, Yeh LJ, Kuo CC. Importance of reinfection in the pathogenesis of trachoma Rev Infect Dis 1985, 7:717-725.
80. Brade L, Nurminen M, Mäkelä PH, Brade H: Antigenic properties of Chlamydia trachomatis lipopolysaccharide. Infect Immun 1985, 48:569-572.
81. Ingalls RR, Rice PA, Qureshi N, Takayama K, Lin JS, Golenbock DT: The inflammatory cytokine response to Chlamydia trachomatis infection is endotoxin. Infect Immun 1995, 63:3125-3130
82. Juvonen J, Juvonen T, Launla A, Kuusisto J, Alarakkola E, Särkioja T, et al: Can degenerative aortic valve stenosis be related to persistent Chlamydia pneumoniae infection? Ann Intern Med 1998, 128:741-744.
83. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q: Is atherosclerosis an immunologically mediated disease? Immunol Today 1995, 16:27-33
84. Nakano Y, Inai Y, Yamashita Y, Nagaoka S, Kusuzaki-Nagira T, Nishihara T, et al: Molecular and immunological characterization of a 64-kDa protein of Actinobacillus actinomycetemcomitans Oral Microbiol Immunol 1995, 10:151-159.
85. Kikuta LC, Puolakkainen M, Kuo CC, Campbell LA: Isolation and sequence analysis of the Chlamydia pneumonias GroE operon. Infect Immun 1991, 59:4665-4669.
86. Kol A, Sukhova GK, Lichtman AH, Libby P: Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-α and matrix metalloproteinase expression. Circulation 1998, 98:300-307. This article enhances understanding of the link between C. pneumonias autoimmunity and atherosclerosis.
87. Bimie DH, Holme ER, McKay IC, Hood S, McColl KE, Hillis WS: Association between antibodies to heat shock protein 65 and coronary atherosclerosis: possible mechanism of action of Helicobacter pylori and other bacterial infections in increasing cardiovascular risk. Eur Heart J 1998, 19:387-394.
88. Patel P, Mendall MA, Carrington D, Strachan DP, Leatham E, Molineaux N, et al. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors. BMJ 1995, 311:711-714.
89. Toss H, Gnarpe J, Gnarpe H, Siegbahn A, Lindahl B, Wallentin L: Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease. Eur Heart J 1998, 19:570-577.
90. Laurila A, Bloigu A, Näyhä S, Hassi J, Leinonen M, Saikku P: Chronic Chlamydia pneumoniae infection is associated with a serum lipid profile known to be a risk factor for atherosclerosis. Arterioscler Thromb Vasc Biol 1997, 17:2910-3913.
91. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. for the Cholesterol and Recurrent Events (CARE) Investigators: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Circulation 1998, 98:839-844. A nested case-control study of a large secondary prevention trial demonstrates that plasma levels of C-reactive protein and serum amyloid A predict the risk of recurrent coronary events among stable patients with a history of prior myocardial infarction. The data also raise the possibility that the effect of inflammation on coronary risk may be attenuated by pravastatin therapy.
92. Miller MD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-875. This article reports on unusual side effects of antiviral therapy in AIDS patients. The pattern of body fat redistribution resembles that of the metabolic syndrome regarded as a major risk factor for coronary atherosclerosis.
93. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daley J: Severe premature coronary artery disease with protease inhibitors. Lancet 1998, 351:1328. This article reports on the extremely rapid progression of atherosclerosis in AIDS patients treated with a novel antiviral regimen. This first report has been followed by many other reports.